Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
1. In this large case-control study across 7 tertiary pediatric hospitals, receiving Nirsevimab (Beyfortus) among symptomatic infants with respiratory syncytial...







